Tag: NSCLC)

Gastroenterology

Study shows disparities in guideline-concordant treatment for NSCLC patients

Newsemia
Lung cancer is the leading cause of cancer-associated deaths in the United States. Non-small cell lung cancer (NSCLC), a group of lung cancers named for...
Latest News

Plasma monitoring of EGFR mutations in NSCLC may help predict resistance to tyrosine kinase inhibitors

Newsemia
Oncotarget Volume 11, Issue 11 reported that at clinical progression, 64 EGFR T790M plasma positive patients were subjected to second line-treatment with osimertinib and strictly...
Latest News

Administering immunotherapy alongside chemoradiation for advanced NSCLC appears to be safe and tolerable

Newsemia
Research from Rutgers Cancer Institute of New Jersey shows administering the immunotherapy drug pembrolizumab together with chemotherapy given at the same time as radiation treatment...
Pharma / Biotech

Safety, Clinical Activity and Pharmacokinetics of Alflutinib (AST2818) in Advanced NSCLC Patients with EGFR T790M Mutation.

Newsemia
Related Articles Safety, Clinical Activity and Pharmacokinetics of Alflutinib (AST2818) in Advanced NSCLC Patients with EGFR T790M Mutation. J Thorac Oncol. 2020 Jan 30;: Authors:...
Latest News

Samenvatting: Takeda presenteert langetermijngegevens in ALK + NSCLC met ALUNBRIG® (brigatinib) blijft superioriteit in de eerstelijn aantonen na twee jaar follow-up

Newsemia
CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502 / NYSE: TAK) heeft vandaag bijgewerkte gegevens bekendgemaakt van de Fase 3 ALTA-1L-studie, die...
Latest News

Takeda presenta los datos de largo plazo de ALUNBRIG (brigatinib) en ALK+ NSCLC ® que continúan demostrando la superioridad en la primera línea después de dos años de seguimiento

Newsemia
CAMBRIDGE, Massachusetts y OSAKA, Japón–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) anunció hoy los datos actualizados del estudio de fase 3 ALTA-1L, que evaluó a ALUNBRIG...
Latest News

Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up

Newsemia
CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced updated data from the Phase 3 ALTA-1L trial, which evaluated ALUNBRIG versus crizotinib...
Latest News

Riassunto: Takeda presenta i dati a lungo termine relativi a ALK+ NSCLC che mostrano come ALUNBRIG® (brigatinib) continui a dimostrare superiorità nella prima linea dopo due anni di follow-up

Newsemia
CAMBRIDGE, Massachusetts e OSAKA, Giappone–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) oggi ha annunciato dati aggiornati dalla Fase 3 della sperimentazione clinica ALTA-1L, nel corso della...
Pharma / Biotech

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR-mutation Positive NSCLC Patients.

Newsemia
Related Articles A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR-mutation Positive NSCLC Patients. J...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World